Drug Trial Radar · NCT05176639
A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Nov 16, 2022
Primary completion
Jul 15, 2024
Study completion Mar 27, 2025
Sponsor
- Lead sponsor
- Viridian Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in participants with thyroid eye disease (TED). The primary objective of this clinical trial is to establish the safety, tolerability, and efficacy of veligrotug, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of veligrotug in active TED participants who received 10 milligrams (mg)/kilogram (kg).
Conditions
- Thyroid Eye Disease
Interventions
VeligrotugDrug
5 IV Infusions of veligrotug 10 mg/kg
PlaceboDrug
5 IV Infusions of veligrotug matched placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proptosis Responder Rate (PRR) in the Study Eye As Measured by ExophthalmometerTime frame: Baseline to Week 15
Locations
53 sites in 7 countries. Site status is shown where the registry gives one.
University of Colorado - Department of Ophthalmology
Aurora, California
The Private Office of Raymond Douglas
Beverly Hills, California
USC Roski Eye Institute
Los Angeles, California
MACRO Trials, Inc.
Los Angeles, California
Amy Patel Jain, MD
Newport Beach, California
Byers Eye Institute/Stanford University
Palo Alto, California
Senta Clinic
San Diego, California
University of California, San Francisco
San Francisco, California
University of Colorado
Aurora, Colorado
Sina Medical Center
Homestead, Florida
Med-Care Research Inc.
Miami, Florida
Edward Jenner Research Group Center LLC
Plantation, Florida
Sarasota Retina Institute
Sarasota, Florida
Vision Medical Research Inc.
Orland Park, Illinois
University Health Diabetes, Endocrinology & Nephrology Center
Kansas City, Kansas
KU Medical Center, University of Kansas
Kansas City, Kansas
Massachusetts Eye and Ear
Boston, Massachusetts
Ophthalmic Consultants of Boston
Weymouth, Massachusetts
Fraser Eye Care Center
Fraser, Michigan
Kahana Oculoplastic & Orbital Surgery
Livonia, Michigan
University of Minnesota, Department of Ophthalmology and Visual Neurosciences
Minneapolis, Minnesota
Advanced Research International, LLC
Las Vegas, Nevada
Rutgers-New Jersey Medical School-Newark
Newark, New Jersey
New York Eye Ear Infirmary of Mount Sinai
New York, New York
Baylor College of Medicine (BCM)-Ophthalmology
Houston, Texas
Neuro-Eye Clinical Trials
Houston, Texas
Neuro-Ophthalmology of Texas PLLC
Houston, Texas
University of Vermont Medical Center
Burlington, Vermont
West Virgina University Eye Institute
Morgantown, West Virginia
Sydney Eye Hospital
Sydney, Australia
North Shore Eye Surgery
Sydney, Australia
CHU d'Angers
Angers, France
CH Nice
Nice, France
Centre Hospitalier National D'ophtalmologie
Paris, France
AP-HP- Hopital de la Pitie Salpetriere
Paris, France
Universitatsmedizin Gottingen
Göttingen, Germany
Johannes Gutenberg-University Medical Center
Mainz, Germany
NZOZ E-Vita
Bialystok, Poland
Specjakistyczny Osrodek Okulistyczny Oculomedica
Bydgoszcz, Poland
Santa Familia PTG Lodz
Lodz, Poland
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.